Actively Recruiting
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study
Led by Umeå University · Updated on 2022-11-30
300
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
Umeå University
Lead Sponsor
U
University Hospital, Linkoeping
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are observing patients with borderline resectable and locally advanced pancreatic cancer to assess overall survival, quality of life, and surgical removal rates. The study includes patients treated at Nordic hospitals, focusing on those with non-endocrine pancreatic cancer as defined by established clinical guidelines. The goal is to understand outcomes in real-world treatment settings without altering care. The study is observational and does not involve any experimental treatment. Participants are identified through regional tumor boards and followed to track their treatment compliance, response to chemotherapy, and quality of life at multiple time points ranging from initial inclusion up to 24 months. Researchers will also evaluate factors predicting the possibility of surgical removal of the tumor. During the study, participants will have their quality of life assessed at baseline and at 3, 6, 9, 12, and 24 months after enrollment. Outcomes like median overall survival and surgical resection rates will be monitored for up to 72 months or until death. The study involves collecting clinical data and patient-reported information over several years to gain insights into the disease course and treatment impact.
CONDITIONS
Brief Title
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed or suspected invasive pancreatic primary tumor
- Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines
- Adults aged 18 years or older
You will not qualify if you...
- Suspected endocrine tumor
- Suspected non-pancreatic periampullary tumor
- Distant metastasis
- Age under 18 years
- Patient unable to understand verbal or written information interfering with informed consent or treatment
- Mental or organic disorder interfering with informed consent or treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 72 months
Participants are observed over time to assess survival, quality of life, and tumor resectability according to routine clinical care.
Assessments at baseline, 3, 6, 9, 12, and 24 months after inclusion
Trial Site Locations
Total: 1 location
1
Surgical Clinic at Umeå University Hospital
Umeå, Sweden, 90185
Actively Recruiting
Research Team
O
Oskar Franklin, MD/PhD
A
Agneta Karhu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here